Global Human Immune Globulin Intravenous Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Immune Globulin Intravenous Market Research Report 2024
Immune globulin (Ig) short-term protection against hepatitis A and measles
According to Mr Accuracy reports new survey, global Human Immune Globulin Intravenous market is projected to reach US$ 21770 million in 2029, increasing from US$ 13360 million in 2022, with the CAGR of 7.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Immune Globulin Intravenous market research.
The market growth can be attributed to several factors. Firstly, the increasing prevalence of bleeding disorders, driven by factors such as genetic predisposition, aging population, and improved diagnostic capabilities, has fueled the demand for coagulation factor products. Additionally, advancements in recombinant DNA technology and biotechnology have enabled the development of highly purified and more effective coagulation factor concentrates, offering improved treatment options for patients.Furthermore, the rising awareness about bleeding disorders and the availability of comprehensive treatment programs have contributed to increased diagnosis rates and access to coagulation factor therapies. Improved reimbursement policies and healthcare infrastructure have also played a role in expanding market reach.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Immune Globulin Intravenous market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Takeda
Grifols
CSL
Octapharma
Biotest
Kedrion
Hualan Bio
CNBG
Shanghai RAAS
CBPO
LFB Group
BPL
Sichuan Yuanda Shuyang
Segment by Type
IVIg Liquid
IVIg Powder
Immunodeficiency
Autoimmune Disease
Acute Infection
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Human Immune Globulin Intravenous report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Human Immune Globulin Intravenous market is projected to reach US$ 21770 million in 2029, increasing from US$ 13360 million in 2022, with the CAGR of 7.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Immune Globulin Intravenous market research.
The market growth can be attributed to several factors. Firstly, the increasing prevalence of bleeding disorders, driven by factors such as genetic predisposition, aging population, and improved diagnostic capabilities, has fueled the demand for coagulation factor products. Additionally, advancements in recombinant DNA technology and biotechnology have enabled the development of highly purified and more effective coagulation factor concentrates, offering improved treatment options for patients.Furthermore, the rising awareness about bleeding disorders and the availability of comprehensive treatment programs have contributed to increased diagnosis rates and access to coagulation factor therapies. Improved reimbursement policies and healthcare infrastructure have also played a role in expanding market reach.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Immune Globulin Intravenous market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Takeda
Grifols
CSL
Octapharma
Biotest
Kedrion
Hualan Bio
CNBG
Shanghai RAAS
CBPO
LFB Group
BPL
Sichuan Yuanda Shuyang
Segment by Type
IVIg Liquid
IVIg Powder
Segment by Application
Immunodeficiency
Autoimmune Disease
Acute Infection
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Human Immune Globulin Intravenous report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices